Vir Biotechnology (VIR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.57
- Estimate
- -$0.75
- Surprise
- +23.5%
- Score today
- 5.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Vir Biotechnology (VIR) reported a narrower loss than forecast — adjusted EPS of -$0.57 against the -$0.75 estimate (a 23.5% beat on a still-unprofitable quarter).
Coverage in the report window
- Needham Maintains Buy Rating and Raises Price Target for Vir Biotechnology — fiscal.ai, 2026-11-05
- Vir Biotechnology to Present Phase 3 ECLIPSE 1 Data at AASLD The Liver Meeting 2026 — fiscal.ai, 2026-11-05
- Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20 — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates VIR Sell at 5.9/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +23.5% surprise compares with a -67.3% four-quarter average. Next scheduled report: 2027-02-24.
What argues against it
- Concentration risk — Counterparty: PRO-XTEN platform license (Sanofi/Amunix)
- Quality below floor (3.4 < 4.0)
- Value-trap signals (4/5): Margin compression (op margin -81.6%), High leverage (D/E 1.7), Material insider selling (3 sells, 0.03% of cap)…
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.98
- Price target
- $18.27
- Stop
- $11.15
- Upside to target
- +52.4%
- Reward-to-risk
- 3.5:1
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
VIR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.86B
- P/E (fwd)
- -4.5
- 52-week range
- $4.82–$12.19
- Off 52-week high
- 1.7%
- RSI (14)
- 65
- Volume vs avg
- 0.26×
- Score today
- 5.9/10